Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
Ilaria Attili, Carla Corvaja, Gianluca Spitaleri, et al.
Cancers (2023) Vol. 15, Iss. 20, pp. 5079-5079
Open Access | Times Cited: 16

Showing 16 citing articles:

Advancements in fourth-generation EGFR TKIs in EGFR-mutant NSCLC: Bridging biological insights and therapeutic development
Carla Corvaja, Antonio Passaro, Ilaria Attili, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102824-102824
Closed Access | Times Cited: 9
Formulation and Evaluation of Lipid/Soluplus-Stabilized Nanocrystals of Paclitaxel and Bosutinib for a Synergistic Effect in Non-Small Cell Lung Cancer Therapy
Manish Kumar, Pooja Goswami, Abhishek Jha, et al.
Molecular Pharmaceutics (2025)
Closed Access
Debate on first-line treatment strategies in advanced non-small cell lung cancer with EGFR mutation: An expert panel meeting by the Italian Association of Thoracic Oncology (AIOT)
Cesare Gridelli, Tony Mok, Pasi A. Jänne, et al.
Lung Cancer (2025) Vol. 201, pp. 108100-108100
Closed Access
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy
Anna De Lucia, L. Mazzotti, Anna Gaimari, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Arachidonic acid suppresses lung cancer cell growth and modulates lipid metabolism and the ERK/PPARγ signaling pathway
Lin Wang, Lanlan Wei, Xueling Chen, et al.
Lipids in Health and Disease (2025) Vol. 24, Iss. 1
Open Access
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario
Valeria Fuorivia, Ilaria Attili, Carla Corvaja, et al.
Current Oncology (2024) Vol. 31, Iss. 9, pp. 5121-5139
Open Access | Times Cited: 3
Harnessing Pyroptosis for Lung Cancer Therapy: The Impact of NLRP3 Inflammasome Activation
Rajiv Dahiya, Vijaykumar Sutariya, Sheeba Varghese Gupta, et al.
Pathology - Research and Practice (2024) Vol. 260, pp. 155444-155444
Closed Access | Times Cited: 2
Alectinib vs. Lorlatinib in the Front-Line Setting for ALK-Rearranged Non-Small-Cell Lung Cancer (NSCLC): A Deep Dive into the Main Differences across ALEX and CROWN Phase 3 Trials
Ilaria Attili, Valeria Fuorivia, Gianluca Spitaleri, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2457-2457
Open Access | Times Cited: 2
Coccinic acid exhibits anti-tumor efficacy against NSCLC harboring EGFR L858R/T790M mutation via the EGFR/STAT3 pathway
Peiyuan Sun, Shuanggou Zhang, Yana Qu, et al.
Bioorganic Chemistry (2024) Vol. 154, pp. 108038-108038
Closed Access | Times Cited: 2
Adiponectin Receptor Agonist AdipoRon Inhibits Proliferation and Drives Glycolytic Dependence in Non-Small-Cell Lung Cancer Cells
Sanober Kafeel, Angela Ragone, Alessia Salzillo, et al.
Cancers (2024) Vol. 16, Iss. 15, pp. 2633-2633
Open Access | Times Cited: 1
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer
Se‐Hoon Lee, Jessica Menis, T.M. Kim, et al.
ESMO Open (2024) Vol. 9, Iss. 12, pp. 103996-103996
Closed Access | Times Cited: 1
Nucleolar casein kinase 2 alpha as a prognostic factor in patients with surgically resected early‑stage lung adenocarcinoma
Satoshi Muto, Yoshimi Homma, Yuichiro Kiko, et al.
Oncology Reports (2024) Vol. 53, Iss. 1
Closed Access
Diagnostics and Therapy for Malignant Tumors
Chih‐Yang Tsai, Chunyu Wang, Hasok Chang, et al.
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2659-2659
Open Access
The ‘Liaisons dangereuses’ Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation
Umberto Zanini, Paola Faverio, Valentina Bonfanti, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7085-7085
Open Access
Novel Cyclic Peptide–Drug Conjugate P6-SN38 Toward Targeted Treatment of EGFR Overexpressed Non-Small Cell Lung Cancer
Andrii Bazylevich, Anthony R. Miller, Irina G. Tkachenko, et al.
Pharmaceutics (2024) Vol. 16, Iss. 12, pp. 1613-1613
Open Access
Targeting c-Met in Breast Cancer: From Mechanisms of Chemoresistance to Novel Therapeutic Strategies
Emeka Iweala, Doris Nnenna Amuji, Abimbola Mary Oluwajembola, et al.
Current Research in Pharmacology and Drug Discovery (2024) Vol. 7, pp. 100204-100204
Open Access
Page 1

Scroll to top